Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257254 · ClinicalTrials.gov registry record
Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 76
- Enrollment target
NCT03257254: Completed study, sponsored by Boston Scientific Corporation.
NCT03257254 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03257254 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
Study Summary
A 12 month, multicenter, open-label registry to observe chronic venous insufficiency resulting in VLU treated with Varithena.
Primary Outcome
Mean change in wound perimeter as measured by photograph inputted into wound measuring technology platform. Larger number indicates a lower wound perimeter compared to baseline. Epithelial migration measured by change in perimeter of wound.
Interventions
- DRUG Varithena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2020-09-28 |
What the finished NCT03257254 record still lists
NCT03257254 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 76 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Varithena is the first listed.
NCT03257254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03257254 about?
NCT03257254 is a clinical study titled "Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)". A 12 month, multicenter, open-label registry to observe chronic venous insufficiency resulting in VLU treated with Varithena.
What is the current status of trial NCT03257254?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2017-09-29. Estimated completion is 2020-09-28.
What interventions are being tested in trial NCT03257254?
The interventions under investigation include: Varithena (DRUG).
Who is sponsoring clinical trial NCT03257254?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI